Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of November 2018. The report primarily serves to incorporate by reference a press release dated November 7, 2018, announcing the Company's Third Quarter 2018 results. Additionally, the filing references a significant strategic development from October 2018 involving a collaboration with Bristol-Myers Squibb Company (BMS).
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) which is incorporated by reference but not detailed in the body of this Form 6-K.
Material Changes and Strategic Developments
- Bristol-Myers Squibb Collaboration: On October 10, 2018, Compugen entered into a Master Clinical Trial Collaboration Agreement and a Securities Purchase Agreement with BMS.
- Exhibit Filings: Redacted copies of the Master Clinical Trial Collaboration Agreement and the Securities Purchase Agreement are filed as Exhibits 10.1 and 10.2, respectively.
- Confidentiality: Certain portions of the Master Clinical Trial Collaboration Agreement (Exhibit 10.1) have been redacted pending confidential treatment requests with the SEC.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook figures, or detailed management commentary regarding future performance. It notes that the information is incorporated into the Company's Registration Statement on Form F-3 (File No. 333-213007). No specific risks or contingencies are detailed in the text of this Form 6-K, other than the standard incorporation of the referenced press release.
Investor Verification Checklist
- Review the full text of the November 7, 2018 press release (Exhibit 99.1) for specific Q3 2018 financial results.
- Examine the redacted Master Clinical Trial Collaboration Agreement (Exhibit 10.1) to understand the scope of the BMS partnership.
- Analyze the Securities Purchase Agreement (Exhibit 10.2) to determine the financial terms and capital raised from BMS.
- Verify the impact of the BMS collaboration on the Company's cash position and future revenue streams.